Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 7/20 | 0.51 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 2/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462368 | 0.99 | VIPR2 (0.50) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30543189 | 0.98 | VIPR2 (0.53) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30362779 | 0.98 | VIPR2 (0.53) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30741250 | 0.95 | VIPR2 (0.56) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29466598 | 0.92 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29520980 | 0.88 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29778027 | 0.88 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30107616 | 0.87 | F2 (0.49) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30798736 | 0.87 | F2 (0.53) | VIPR2VIPR1F2NTSR2NTSR1 | |
| SCHEMBL29903357 | 0.86 | VIPR1 (0.54) | VIPR2VIPR1BACE1BACE2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377142-B2 | Recombinant pseudocowpoxvirus | TRANSGENE (FR) | 2025-08-05 | — | — | US | disclosed |
| US-20240325560-A1 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | ABLEVIA BIOTECH GMBH (AT) | 2024-10-03 | — | — | US | disclosed |
| US-12011484-B2 | Compound for the sequestration of undesirable antibodies in a patient | ABLEVIA BIOTECH GMBH (AT) | 2024-06-18 | — | — | US | disclosed |
| US-11986536-B2 | Compound for the sequestration of undesirable antibodies in a patient | ABLEVIA BIOTECH GMBH (AT) | 2024-05-21 | — | — | US | disclosed |
| US-20230381328-A1 | COMPOUND FOR THE PREVENTION OR TREATMENT OF MYASTHENIA GRAVIS | ABLEVIA BIOTECH GMBH (AT) | 2023-11-30 | — | — | US | disclosed |
| US-20230381334-A1 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | ABLEVIA BIOTECH GMBH (AT) | 2023-11-30 | — | — | US | disclosed |
| US-20230365655-A1 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | ABLEVIA BIOTECH GMBH (AT) | 2023-11-16 | — | — | US | disclosed |
| US-20230355784-A1 | COMPOUND FOR THE PREVENTION OR TREATMENT OF AUTOANTIBODY-MEDIATED CONDITIONS | ABLEVIA BIOTECH GMBH (AT) | 2023-11-09 | — | — | US | disclosed |
| US-20230355747-A1 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | ABLEVIA BIOTECH GMBH (AT) | 2023-11-09 | — | — | US | disclosed |
| US-20230355660-A1 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTI-PEG ANTIBODIES IN A PATIENT | ABLEVIA BIOTECH GMBH (AT) | 2023-11-09 | — | — | US | disclosed |
| EP-4217006-A1 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | Ablevia biotech GmbH (AT) | 2023-08-02 | — | — | EP | disclosed |
| EP-4217402-A1 | COMPOUND FOR THE PREVENTION OR TREATMENT OF AUTOANTIBODY-MEDIATED CONDITIONS | Ablevia biotech GmbH (AT) | 2023-08-02 | — | — | EP | disclosed |
| EP-4217381-A1 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | Ablevia biotech GmbH (AT) | 2023-08-02 | — | — | EP | disclosed |
| EP-3898702-B1 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | ABLEVIA BIOTECH GMBH (AT) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022063879-A1 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | ABLEVIA BIOTECH GMBH (AT) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022063887-A1 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | ABLEVIA BIOTECH GMBH (AT) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022063885-A1 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTI-PEG ANTIBODIES IN A PATIENT | ABLEVIA BIOTECH GMBH (AT) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022063882-A1 | COMPOUND FOR THE PREVENTION OR TREATMENT OF AUTOANTIBODY-MEDIATED CONDITIONS | ABLEVIA BIOTECH GMBH (AT) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022063892-A1 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | ABLEVIA BIOTECH GMBH (AT) | 2022-03-31 | — | — | WO | disclosed |
| EP-3960769-A1 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | Ablevia biotech GmbH (AT) | 2022-03-02 | — | — | EP | disclosed |